Postoperative Treatment in a Patient After Hemithyroidectomy: the Therapeutic Challenges of a Hidden Thyrotropinoma

  • Sabine Vermeersch Universitair Ziekenhuis Brussel, Brussel, Belgium
  • Kris Poppe CHU St-Pierre, Brussel, Belgium
  • David Unuane Universitair Ziekenhuis Brussel, Brussel, Belgium
  • Brigitte Velkeniers Universitair Ziekenhuis Brussel, Brussel, Belgium


Thyroid nodule, thyrotropinoma, hyperthyroidism, hemithyroidectomy, somatostatin analogues.


Objectives: We report the unusual case of a patient with a thyrotropinoma, discovered after a hemithyroidectomy for a suspicious thyroid nodule, and its therapeutic challenges.
Materials and methods: In a patient who underwent hemithyroidectomy for cold thyroid nodule, hyperthyroid symptoms persisted, despite stopping levothyroxine treatment. Further investigation was carried out through the following laboratory tests: thyroid-stimulating hormone (TSH) test; free thyroxine (fT4) test; and the thyrotropin releasing hormone (TRH) test. A pituitary magnetic resonance imaging (MRI) scan and genetic analysis was also carried out. The test results confirmed the diagnosis of a thyrotropinoma.
Results: Treatment with long-acting somatostatin analogues normalised thyroid hormones and symptoms of hyperthyroidism.
Conclusion: The diagnostic approach to the thyroid nodule should include a detailed clinical and biochemical examination. Initial biochemical evaluation by TSH alone does not allow detecting inappropriate TSH secretion that may increase the risk of thyroid malignancy. In case of a thyrotropinoma, the ideal treatment consists of combined care of central and peripheral thyroid disease.



  • Caron P. Thyrotropin-secreting pituitary adenomas. Presse med 2009;38:107–111.
  • Beck-peccoz P, Persani L, Mannavola D et al. TSH-secreting adenomas. Best Pract Res Clin Endocrinol Metab 2009;23:597-606.
  • Welker MJ, Orlov D. Thyroid nodules. Am Fam Physician 2003;67:559-66.
  • Alba M, Fintini D, Lovicu RM et al. Levothyroxine therapy in preventing nodular recurrence after hemithyroidectomy: a retrospective study. J Endocrinol Invest 2009;4:330-4.
  • Gasparoni P, Rubello D, Persani L et al. Unusual association between a thyrotropin-secreting pituitary adenoma and a papillary thyroid carcinoma. Thyroid 1998;8:181-183.
  • Unluturk U, Sriphrapradang C, Erdogan M et al. Management of differentiated thyroid cancer in the presence of resistance to thyroid hormone and TSH-secreting adenomas: a report of four cases and Review of Literature. J Clin Endocrinol Metab 2013;98:2210-2217.
  • McLeod DS, Watters KF, Carpenter AD et al. Thyrotropin and thyroid cancer diagnosis: a systematic review and dose-response meta-analysis. J Clin Endocrinol Metab 2012;97:2682-2692.
  • Paschke R, Hegedus L, Alexander E et al. Thyroid nodule guidelines: agreement, disagreement and need for future research. Nat Rev Endocrinol 2011;7:354-61.
  • Kishida M, Otsuka F, Kataoka H et al. Hyperthyroidism in a patient with THS-producing pituitary adenoma coexisting with thyroid papillary adenocarcinoma. Endocrinol J 2000;47:731-738.
  • Nguyen HD, Galitz MS, Mai VQ et al. Management of coexisting thyrotropin/growth hormone-secreting pituitary adenoma and papillary thyroid carcinoma: a therapeutic challenge. Thyroid 2010;20:99-103.
  • Published: 2015-07-29

    Issue: Vol. 2 No. 5 (2015) (view)

    Section: Articles

    How to cite:
    Vermeersch S, Poppe K, Unuane D, Velkeniers B. Postoperative Treatment in a Patient After Hemithyroidectomy: the Therapeutic Challenges of a Hidden Thyrotropinoma. EJCRIM 2015;2 doi:10.12890/2015_000217.